Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM GAM HOLDING AG, GAM INTERNATIONAL MANAGEMENT LIMITED AND TAUBE HODSON STONEX PARTNERS LLP

ABLYNX
Posted on: 06 Sep 16

GHENT, Belgium, 6 September 2016 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from GAM Holding AG, GAM International Management Limited and Taube Hodson Stonex Partners LLP.

 

GAM International Management Limited notified Ablynx that they have crossed the 3% threshold on 31 August 2016 following the acquisition of Taube Hodson Stonex (THS) Partners by GAM and now hold 2,408,585 Ablynx shares, representing 3.95% of the current 60,910,744 outstanding Ablynx shares. As a result of the transfer of the investment business of THS Partners to GAM International Limited, THS Partners no longer hold any Ablynx shares (from 2,410,681 held previously), and thus have dropped below the lowest threshold.

 

Following the acquisition of Taube Hodson Stonex (THS) Partners by GAM on 31 August 2016, GAM International Management Limited has been appointed as investment advisor to all THS funds, replacing Taube Hodson Stonex Partners LLP. On 27 July 2015, THS disclosed a shareholding in Ablynx of 2,410,681 shares which represented 4.42% of the 54,487,457 outstanding Ablynx shares at that time. 

 

Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

 

 

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

 

For more information, please contact

Ablynx:

Dr Edwin Moses

CEO

t:   +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e:  edwin.moses@ablynx.com

 

Marieke Vermeersch

Director IR & Corporate Communications

t:   +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e:  marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

 

 

Ablynx media/analyst relations

FTI Consulting:

Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss

t: +44 20 3727 1000

e: ablynx@fticonsulting.com

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 06/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.